The level of malondialdehyde-modified LDL and LDL immune complexes in patients with rheumatoid arthritis

Clin Biochem. 2009 Sep;42(13-14):1352-7. doi: 10.1016/j.clinbiochem.2009.05.016. Epub 2009 Jun 6.


Objectives: To explore possible associations of malondialdehyde-modified low-density lipoprotein (MDA-LDL) and LDL-immune complexes (LDL-IC) with atherosclerosis in rheumatoid arthritis (RA).

Design and methods: Plasma MDA-LDL, LDL-IC levels and mechanisms of the changes were investigated in RA patients with or without coronary artery disease (CAD), simple CAD patients and control.

Results: MDA-LDL and LDL-IC levels were found increased in all the studied patients, the RA patients with CAD exhibited the most significant changes. MDA-LDL levels were higher in the RA patients with CAD than those both in the simple RA and CAD patients. Multiple linear regression analysis showed that CAD, LDL-IC and erythrocyte sedimentation rate accounted for 36.5% of the variation in MDA-LDL levels; and age, activity, MDA-LDL and rheumatoid factors accounted for 34.5% of the variation in LDL-IC.

Conclusions: High levels of MDA-LDL and LDL-IC are risk factors for increased risk of atherosclerosis in RA patients and are associated with inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antigen-Antibody Complex / blood*
  • Antigen-Antibody Complex / chemistry
  • Arthritis, Rheumatoid / blood*
  • Arthritis, Rheumatoid / complications
  • Blood Sedimentation
  • C-Reactive Protein / analysis
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / complications
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Linear Models
  • Lipoproteins, LDL / blood*
  • Lipoproteins, LDL / chemistry
  • Lipoproteins, LDL / immunology
  • Male
  • Malondialdehyde / blood*
  • Malondialdehyde / chemistry
  • Middle Aged
  • Rheumatoid Factor / blood


  • Antigen-Antibody Complex
  • Lipoproteins, LDL
  • Malondialdehyde
  • C-Reactive Protein
  • Rheumatoid Factor